DIVERSIFIED PIPELINE

DISCOVERED USING PHARMA.AI

INNOVATIVE AND ACCELERATED INTERNAL DRUG CANDIDATES

• Total Number of Programs: 40+
• Preclinical Candidates Nominated from 2021: 31
• Preclinical Candidates Nominated in 2022: 9
• Pipelines received IND approval: 13

INDICATION

• Phase II
• Target ID
• Lead Opt.
• IND-enabling
• Hit-to-Lead

Publications

• Publications 1
• Nature Biotech 1
• Publications 2
• Publications 3
• Cell TIPS
• Nature Biotech 2

Contact bd@insilicomedicine.com for partnering opportunities.

Insilico Medicine 2-page Overview

• Download Overview

COLLABORATIONS AND PARTNERSHIPS

The rapid progress of internal pipeline demonstrates the generative-AI driven drug discovery capabilities of our Pharma.AI platform consisting of Biology42, Chemistry42, and Medicine42.

Our collaboration partners can leverage our technology and development capabilities to augment and accelerate their discovery and development initiatives.

Partnership Highlights

• TNIK: TNIK Inhibitor - Treating Fibrotic diseases of the Lung and Kidney
• 3CLPro: Orally Available covalent irreversible 3CLPro Inhibitor for the Treatment of COVID-19 and Coronavirus infection
• PHD: Proline Hydroxylase (PHD) Inhibitors - Treatment of Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD)
• QPCTL: Glutaminyl-peptide cyclotransferase-like protein (QPCTL) Inhibitor - Novel cancer immunotherapy for COLD tumors
• USP1: Ubiquitin Specific Protease 1 (USP1) Inhibitor - For the treatment of BRCA-mutant cancer
• MAT2A: Methionine adenosyltransferase 2α (MAT2A) Inhibitor - Treatment of MTAP Deficient Cancer
• KAT6: KAT6 Inhibitor - Treatment of ER+/HER2- Breast Cancer
• ENPP1: Ectonucleotide phosphodiesterase 1 (ENPP1) Inhibitor - Treating anti-PD-1/-L1 resistant cancers
• DGKA: Diacylglycerol kinase A (DGKA) Inhibitor - Treating solid tumors in combination with checkpoint inhibitor
• CDK12: Cyclin-dependent kinase 12 (CDK12) Inhibitor - Treating Tumors by Induction of BRCAness
• TEAD: Pan-TEAD Inhibitor - Treating Mesothelioma, and Solid Tumors
• FGFR2/3: FGFR2/3 Dual Inhibitor - Treatment of Solid Tumors
• KIF18A: KIF18A Inhibitor - Treating chromosomally unstable cancers with TP53 mutations
• WRN: WRN Inhibitor - Treating microsatellite instability-high (MSI-H) cancers